Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01180647 · ClinicalTrials.gov registry record · Phase 3
Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From Jail
A Phase 3 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 3
- Development phase
- 48
- Enrollment target
NCT01180647 is a Phase 3 study that has completed, run by NYU Langone Health. The registered enrollment target is 48 participants.
The verdict
NCT01180647, a Phase 3 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 48 participants
- Enrollment target
Study Summary
This pilot study's primary aim is to compare rates of sustained opioid relapse, defined as self-reported opioid use \>50% (\>15 of 30) of days during the first 30 days following release from jail, among persons treated with XR-NTX pre-release vs. controls not receiving XR-NTX.
Interventions
- DRUG Extended-Release Naltrexone
- BEHAVIORAL Motivational Enhancement Counseling
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2010-05 |
| Est. Completion | 2013-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01180647
The ClinicalTrials.gov registry entry for NCT01180647 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Extended-Release Naltrexone is the first listed.
NCT01180647 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01180647 about?
NCT01180647 is a clinical study titled "Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From Jail". This pilot study's primary aim is to compare rates of sustained opioid relapse, defined as self-reported opioid use \>50% (\>15 of 30) of days during the first 30 days following release from jail, among persons treated with XR-NTX pre-release vs. controls not receiving XR-NTX.
What is the current status of trial NCT01180647?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 48 participants. The study started on 2010-05. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01180647?
The interventions under investigation include: Extended-Release Naltrexone (DRUG), Motivational Enhancement Counseling (BEHAVIORAL).
Who is sponsoring clinical trial NCT01180647?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.